JP2017504331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504331A5 JP2017504331A5 JP2016546969A JP2016546969A JP2017504331A5 JP 2017504331 A5 JP2017504331 A5 JP 2017504331A5 JP 2016546969 A JP2016546969 A JP 2016546969A JP 2016546969 A JP2016546969 A JP 2016546969A JP 2017504331 A5 JP2017504331 A5 JP 2017504331A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- rna
- influenza
- segments
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 20
- 230000002452 interceptive effect Effects 0.000 claims description 13
- 230000002950 deficient Effects 0.000 claims description 9
- 208000037797 influenza A Diseases 0.000 claims description 7
- 108020000999 Viral RNA Proteins 0.000 claims description 6
- 239000003443 antiviral agent Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 241000712431 Influenza A virus Species 0.000 claims description 4
- 108700008625 Reporter Genes Proteins 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 108091081024 Start codon Proteins 0.000 claims description 3
- 108091034135 Vault RNA Proteins 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1400752.0A GB2522615A (en) | 2014-01-16 | 2014-01-16 | Assay and medicament |
| GB1400752.0 | 2014-01-16 | ||
| PCT/GB2015/050094 WO2015107357A1 (en) | 2014-01-16 | 2015-01-16 | Assay and medicament |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504331A JP2017504331A (ja) | 2017-02-09 |
| JP2017504331A5 true JP2017504331A5 (OSRAM) | 2018-02-22 |
| JP6781045B2 JP6781045B2 (ja) | 2020-11-04 |
Family
ID=50239057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546969A Active JP6781045B2 (ja) | 2014-01-16 | 2015-01-16 | アッセイ及び薬剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20160333321A1 (OSRAM) |
| EP (2) | EP3094338B1 (OSRAM) |
| JP (1) | JP6781045B2 (OSRAM) |
| DK (1) | DK3094338T3 (OSRAM) |
| ES (1) | ES2913063T3 (OSRAM) |
| GB (1) | GB2522615A (OSRAM) |
| PL (1) | PL3094338T3 (OSRAM) |
| WO (1) | WO2015107357A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4046689A1 (en) * | 2021-02-18 | 2022-08-24 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Influenza virus defective interfering particles for use in the prophylactic or therapeutic treatment of coronaviridae infection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0408424D0 (en) * | 2004-04-15 | 2004-05-19 | Univ Warwick | Viral assay |
| US20080292658A1 (en) * | 2004-11-11 | 2008-11-27 | Emmie De Wit | Defective Influenza Virus Particles |
| GB2437799B (en) * | 2006-05-24 | 2008-08-13 | Univ Warwick | Defective interfering virus |
| DK2019685T3 (en) * | 2006-05-24 | 2015-02-09 | Univ Warwick | Defective interfering virus |
| GB0822672D0 (en) * | 2008-12-12 | 2009-01-21 | Univ Warwick | Anti-viral protection with viruses containing a defective genome |
| US20130156733A1 (en) * | 2011-12-20 | 2013-06-20 | Philip I. Marcus | Influenza virus populations, methods of use and methods of making thereof |
-
2014
- 2014-01-16 GB GB1400752.0A patent/GB2522615A/en not_active Withdrawn
-
2015
- 2015-01-16 PL PL15701244.4T patent/PL3094338T3/pl unknown
- 2015-01-16 JP JP2016546969A patent/JP6781045B2/ja active Active
- 2015-01-16 DK DK15701244.4T patent/DK3094338T3/da active
- 2015-01-16 WO PCT/GB2015/050094 patent/WO2015107357A1/en not_active Ceased
- 2015-01-16 EP EP15701244.4A patent/EP3094338B1/en active Active
- 2015-01-16 US US15/111,615 patent/US20160333321A1/en not_active Abandoned
- 2015-01-16 EP EP22162159.2A patent/EP4085917A1/en active Pending
- 2015-01-16 ES ES15701244T patent/ES2913063T3/es active Active
-
2018
- 2018-12-21 US US16/230,114 patent/US11339374B2/en active Active
-
2022
- 2022-04-21 US US17/725,982 patent/US20220325251A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538885A5 (OSRAM) | ||
| Goulet et al. | Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity | |
| Nogales et al. | Functional evolution of the 2009 pandemic H1N1 influenza virus NS1 and PA in humans | |
| JP2010227101A5 (OSRAM) | ||
| JP2018520997A5 (OSRAM) | ||
| WO2022251647A1 (en) | Inhibitors of sars-cov-2 viral replication and uses thereof | |
| JP2017532302A5 (OSRAM) | ||
| JP2016534034A5 (OSRAM) | ||
| JP2015517489A5 (OSRAM) | ||
| JP2016537341A5 (OSRAM) | ||
| JP2012065678A5 (OSRAM) | ||
| JP2017534638A5 (OSRAM) | ||
| JP2015186478A5 (OSRAM) | ||
| WO2016075473A3 (en) | Factor ix gene therapy | |
| JP2017524719A5 (OSRAM) | ||
| JP2016513115A5 (OSRAM) | ||
| JP2015533791A5 (OSRAM) | ||
| JP2014516027A5 (OSRAM) | ||
| Thomas et al. | ZBP1/DAI-dependent cell death pathways in influenza A virus immunity and pathogenesis | |
| CN105582526B (zh) | 三叶因子2在制备治疗及预防肺/支气管急性炎症疾病药物方面的应用 | |
| JP2016535787A5 (OSRAM) | ||
| Xu et al. | Influenza virus in community-acquired pneumonia: current understanding and knowledge gaps | |
| CN107208071A (zh) | 用于流感病毒的减弱活疫苗 | |
| JP2015502973A5 (OSRAM) | ||
| Khalil et al. | Antiviral responses versus virus-induced cellular shutoff: a game of thrones between influenza A virus NS1 and SARS-CoV-2 Nsp1 |